The pharmaceutical companies SOMAÍ from Lisbon and Dascoli Pharma from Zurich have announced the expansion of their existing partnership. According to a statement, they intend to jointly launch the Mint Oral Solutions product line developed by SOMAÍ on the Swiss market and to improve patient access to innovative cannabinoid-based medicines across Switzerland. The companies already successfully launched the Essentuals product line from SOMAÍ in Switzerland last year.
Mint Oral Solutions aims to combine pharmaceutical precision with improved patient compliance and treatment adherence. The products are manufactured using an advanced purification process and feature a peppermint terpene mix, which is intended to make long-term treatment courses more pleasant for patients. According to SOMAÍ, each product in this range features a consistent cannabinoid profile and high bioavailability, in addition to quality certified in line with EU-GMP (Good Manufacturing Practice) standards.
Dascoli Pharma AG specializes in the supply, distribution and professional training of medical cannabis. As such, it is an ideal partner for the market launch of SOMAÍ’s medicines in Switzerland. “Our ongoing collaboration with Dascoli Pharma AG allows SOMAÍ to continue expanding access to our cannabinoid formulations through a trusted partner that shares our vision of pharmaceutical integrity and medical compliance”, as Michael Sassano, CEO of SOMAÍ Pharmaceuticals, explains in the statement.
“The patient-oriented design and scientific rigor behind SOMAÍ’s formulations align perfectly with our mission to ensure Swiss patients have access to safe, effective, and innovative cannabinoid-based therapies”, adds Andrew Petronanos, founder and CEO of Dascoli Pharma AG.
